about
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progressionUnique genomic profile of fibrolamellar hepatocellular carcinoma.Sorafenib in advanced hepatocellular carcinomaPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingCost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantationMolecular classification and novel targets in hepatocellular carcinoma: recent advancementsHepatocellular carcinomaHepatocellular carcinomaSystematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialPrognosis of hepatocellular carcinoma: the BCLC staging classificationmicroRNAs and the MYC network: a major piece in the puzzle of liver cancer.Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.Cancer gene discovery in hepatocellular carcinomaChemoembolization for intermediate HCC: is there proof of survival benefit?Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.The current status of liver transplantation for primary hepatic malignancy.Gene expression in fixed tissues and outcome in hepatocellular carcinoma.Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivoExperimental models of hepatocellular carcinomaBacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitisLow dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Chemoembolization for hepatocellular carcinoma.Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.Novel advancements in the management of hepatocellular carcinoma in 2008.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.Expected developments in hepatology.Hepatocellular carcinoma: present status and future prospects.Treatment of hepatocellular carcinoma: is there an optimal strategy?A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationCarcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.
P50
Q24647547-86FF6703-A4F2-488D-A79B-0320ABC281FBQ27853116-178013ED-3329-40F0-BA2C-D7D866F8FF83Q27861075-A0447D6A-44F6-4E02-B67A-00060DD1677EQ28296761-F3A210EA-0584-4D12-9097-64CB31119221Q28344370-B0E6BC93-BA34-4ED5-BE3E-B9D7B6F15D90Q28383646-CC005A81-ACE6-4B7F-93C7-803D1E8CD1BBQ29615841-2BDF0636-FEAE-4117-9D7B-CA608872A1AEQ29616359-D9442CDA-9242-4664-8CA3-258C13157862Q29616865-4C9E8466-DB71-46DD-9B0C-FD0A26C88FE9Q29617955-5B0A06FD-0048-45EA-9F68-EE72124FAD37Q29619984-7718449B-3EED-4400-801E-4B70D17D334DQ33351051-B83F1F30-5E6E-4211-881F-474EE231E283Q33807832-6FF66C51-ED4C-4AC8-9F54-266050B02D58Q33820376-90DA47BB-DDE0-4155-BF8C-3D21BEF0B0D0Q33907588-8F4C8DBC-105A-4747-AB06-DDD29A11D4F2Q34002120-BFDEE994-91ED-4081-9873-2EB656E95CBCQ34050999-A1234A00-12DC-4BC6-9EF5-7377AB91CBB1Q34068152-33237009-256D-4DF6-B01D-61564D0BD289Q34102411-B1CA24EB-C1A0-4449-BDE0-6A0D23772850Q34170288-7EFC0E32-8628-4D76-96F5-3A0CEB50A09DQ34235518-A686C883-54F4-48FE-ABF6-39AD27DAAAE8Q34268708-FF60DFD6-08A5-4049-A1C5-13C5149C2DBFQ34345987-F3761DF6-77F6-4F49-B373-9B445C42E5D4Q34381820-F06D8C75-F0DA-4782-BB6D-12BFD2B16126Q34409615-7225ABF9-3A6D-4880-B704-05515F629F26Q34505935-379DC35F-EF6C-4A89-B59D-1F6B54095D70Q34547469-1D1F4D50-185C-4D19-877A-6D3E5BA9A678Q34552214-7748C66C-8DCD-471F-A05C-50BBD89FF405Q34552875-B1966AAF-D965-4B8E-98C0-D2F112E4F237Q34572884-FED7AAD0-5BB3-4AF1-B2C4-9B3D13EC7839Q34579605-C360FB8A-DB77-4663-80DC-5AE0D548BC65Q34585928-8D5944BF-0689-406D-9082-2B11616DCF41Q34588842-4C2E59AC-9AEA-4218-9367-1CD4CAEA6165Q34635723-3E055E2B-85BC-4119-8F3C-B82DCF9937D8Q35021178-824BEBA6-ABD5-4A43-8BE7-2B43C0F7741CQ35068060-51F998D9-7F12-48D3-B2A4-CCE56B6BAF92Q35096757-337BB133-4610-4204-9B94-3D21746A7459Q35107005-ED2F2CEA-321A-42C4-9FB5-E182130E181EQ35131908-8B5EA54E-721F-4F20-9D90-2913B814A30EQ35145063-4565989C-D889-4C5B-91B0-E95503FBF64D
P50
description
Spaans onderzoeker
@nl
hulumtues
@sq
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Josep M Llovet
@nl
Josep M Llovet
@sl
Josep M. Llovet
@en
Josep M. Llovet
@es
Josep M. Llovet
@ga
type
label
Josep M Llovet
@nl
Josep M Llovet
@sl
Josep M. Llovet
@en
Josep M. Llovet
@es
Josep M. Llovet
@ga
altLabel
Llovet J
@en
Llovet JM
@en
Llovet Josep M
@en
Llovet Josep Maria
@en
prefLabel
Josep M Llovet
@nl
Josep M Llovet
@sl
Josep M. Llovet
@en
Josep M. Llovet
@es
Josep M. Llovet
@ga
P1053
D-4340-2014
P106
P1153
56004136000
P21
P27
P31
P3829
P496
0000-0003-0547-2667
P569
1954-11-15T00:00:00Z